Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1Phase 2/3 1

Status

Active not recruiting 3Completed 2

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Myeloid 5Plasma cell 3Thoracic 2Other hematologic neoplasm 1Breast 1

Conditions

Myelodysplastic Syndromes 3Primary Myelofibrosis 2Myeloproliferative Disorders 2Thrombocytosis 1Thrombocythemia, Essential 1Recurrence 1Polycythemia Vera 1Polycythemia 1Leukemia, Myeloid, Acute 1

Interventions

Azacitidine 68nilotinib 50Imatinib Mesylate 50ruxolitinib 42Dasatinib 25venetoclax 22Decitabine 20bosutinib 18asciminib 17Cytarabine 15ponatinib 10decitabine and cedazuridine drug combination 10AP 1903 reagent 10Cyclophosphamide 9fludarabine 8Hydroxyurea 8navitoclax 6ON 01910 6sabatolimab 5pevonedistat 5mocetinostat 5luspatercept 5itacitinib 5imetelstat 5givinostat hydrochloride 5givinostat 5fludarabine phosphate 5avapritinib 5Mycophenolic Acid 5Lenalidomide 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × imetelstat × Myeloid × Clear all
NCT05583552 2026-05-12

IMpress

GCP-Service International West GmbH

Phase 2 Active not recruiting
46 enrolled 21 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT02598661 2026-01-05

Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Geron Corporation

Phase 2/3 Active not recruiting
289 enrolled 35 charts 1 FDA
Myeloid

Myelodysplastic Syndromes, Recurrence

NCT04576156 2025-12-04

A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

Geron Corporation

Phase 3 Active not recruiting
327 enrolled
Myeloid

Myeloproliferative Disorders, Polycythemia, Thrombocytosis, Primary Myelofibrosis

NCT01731951 2021-09-21

Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis

Geron Corporation

Phase 2 Completed
80 enrolled 31 charts
Myeloid

Myelodysplastic Syndromes, Myeloproliferative Disorders, Primary Myelofibrosis

NCT01243073 2016-01-26

ET/PV

Geron Corporation

Phase 2 Completed
20 enrolled
Myeloid

Polycythemia Vera, Thrombocythemia, Essential

Data powered by HemOnc (CC BY 4.0) Colophon âš¡